A Phase 2 interventional study of Paclitaxel and Carboplatin in Ovarian Cancer, sponsored by North Eastern German Society of Gynaecological Oncology. Completed at 1 site in Germany. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-03-25.
Sponsored by North Eastern German Society of Gynaecological Oncology · Phase 2, Interventional, and Treatment
The combination of paclitaxel and carboplatin in a three weeks schedule has emerged as the current standard approach for the adjuvant treatment of ovarian cancer. Based on a phase I study now a multi-center phase II-trial was conducted.
2,695 studies on the registry are indexed under Ovarian Neoplasms; 727 are open to participants now.
This study's enrollment of 129 is above the median of 60 across 2,030 interventional studies indexed under Ovarian Neoplasms.
Browse Ovarian Neoplasms studies →North Eastern German Society of Gynaecological Oncology is the lead sponsor of 15 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Paclitaxel · Drug: Carboplatin
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
North Eastern German Society of Gynaecological Oncology